Genmab (GMAB) said Wednesday that worldwide net trade sales of its cancer drug Darzalex, including sales of the subcutaneous product Darzalex Faspro, totaled $4.21 billion in Q2.
Sales of the drug totaled $2.44 billion in the US and $1.77 billion in the rest of the world, the company said.
Genmab receives royalties on net sales of Darzalex under an exclusive worldwide license to Johnson & Johnson (JNJ), the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.